Clinical Characteristics of People With Long-term Type 1 Diabetes

Second Xiangya Hospital of Central South University400 enrolled

Overview

Type 1 diabetes (T1D) is characterized by absolute insulin deficiency. Although the discovery and application of exogenous insulin has prolonged the lifespan of T1D patients, the chronic diabetic complications caused by long-term poor glycemic control will still reduce patients' quality of life and the overall life expectancy. According to the studies focused on long-term T1D, part of the patients with long disease duration showed resistance to microvascular complications, and several protective factors have been identified. The prevalence of T1D in China is extremely low compared to that in the western world, and little is known about the characteristics of patients with long-term T1D in China. Therefore, this study is designed to collect variable clinical and laboratory features of patients with long-term T1D, explore the risk and protective factors for the development of microvascular complications, and provide reference for the prediction and prevention of these complications.

This is a single-center, prospective, observational study. The investigators propose to enroll 400 patients with type 1 diabetes (T1D) ≥10 years. The patients will be followed up annually for 3 years. In order to ensure high quality data, two staff are responsible for the input of original data into the database to check and confirm the accuracy. When the data entered by two people is inconsistent, the auxiliary staff decides which data to use. Missing data will be filled in with the multiple imputation method. The regression analysis will be used to explore the risk and protective factors for the development and progression of microvascular complications.

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Type 1 Diabetes

Interventions

For each follow-up, the glycated albumin(GA) reflecting glycemic control of the past 2-3 weeks, the glycated hemoglobin(HbA1c) reflecting glycemic control of the past 2-3 months, and the advanced glycation end products(AGEs) will be measured.

Residual islet functionBIOLOGICAL

For each follow-up, fasting and stimulated C-peptide levels will be measured.

Genetic variationGENETIC

Genetic variations of interest will be detected with the blood sample collected at baseline.

Dietary constitutesDIETARY_SUPPLEMENT

For each follow-up, the dietary constitutes for the past 3 days will be recorded.

Microbiome composition and functionGENETIC

For each follow-up, the fecal and oral samples will be collected for measurement.

Metabolome compositionBIOLOGICAL

For each follow-up, the serum and urine samples will be collected for measurement.

Composition of peripheral blood immune cellsBIOLOGICAL

For each follow-up, the peripheral blood mononuclear cells will be collected for measurement.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Individuals diagnosed with type 1 diabetes(T1D) according to the 1999 World Health Organization report * Insulin dependence from disease onset * with T1D duration of ≥10 years * able to understand the procedures and methods of this study, voluntarily participate in the study, and agree to sign the informed consent form Exclusion Criteria: * patients with type 2 diabetes, gestational diabetes, or specific types of diabetes * patients with mental disability or have any other condition or disease that may hamper compliance with the protocol

Locations (1)

Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South University

Changsha, Hunan, China

RECRUITING